Key facts
- This page summarizes Michael L. Levitz's Form 4 filing for Anika Therapeutics, Inc. (ANIK).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Aug 2023, 16:30.
Michael L. Levitz - 10 Aug 2023 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)
- Reporting relationship
- EVP, CFO, Treasurer
- Issuer ticker
- ANIK
- Reported as of
- 10 Aug 2023
- Net transaction value
- -$21,051
- SEC form
- 4
- Accepted by SEC
- 11 Aug 2023, 16:30:46 UTC
- Prior SEC filing
- 14 Mar 2023
- Next SEC filing
- 12 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael L. Levitz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael L. Levitz filed Form 4 for Anika Therapeutics, Inc. (ANIK) on 11 Aug 2023.
Change
- Previous filing in this sequence was filed on 14 Mar 2023.
- Current net transaction value: -$21,051.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANIK
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +3,859
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 34,365
- Date
- 10 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
ANIK
transaction
Common Stock
Tax liability
- Transaction value
- $21,051
- Shares
- -1,133
- Change %
- -3.3%
- Price
- $18.58
- Shares after
- 33,232
- Date
- 10 Aug 2023
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANIK
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -3,859
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 10 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,859
- Exercise price
- $0.000000
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on August 10, 2020.
Footnote F2
Includes 668 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 12, 2023.
Footnote F3
Reflects an aggregate of 1,133 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on August 10, 2023.
Footnote F4
Reflects the closing price of ANIK common stock on August 10, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
Footnote F5
Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021.